Modified immune cell therapy for advanced sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 or older.
- You have a soft tissue or bone sarcoma that has spread or cannot be removed with surgery.
- You have had at least one prior chemotherapy or other body-wide treatment for your sarcoma.
- You have tumors that can be measured on scans (at least 2 cm if biopsied).
- You do not have an active autoimmune disease, untreated brain metastases, or certain infections (like hepatitis or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment called lifileucel that uses your own immune cells to fight the cancer. It is for people with a type of soft tissue sarcoma that has not responded to previous treatments.
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Hear when a new Metastatic Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.